Market LIVE
Published markets; coverage varies by country
Product profile · United States

BYFAVO

 ·  Patent Litigation & Settlement History ↓

IngredientREMIMAZOLAM BESYLATE
Application typeNDA
Application212295
Product001
Dosage formPOWDER
RouteINTRAVENOUS
StrengthEQ 20MG BASE/VIAL
Approval date2020-10-06
Marketing statusPrescription
Status event—
ApplicantACACIA
Product source

Current GenericRadar decision

Year2034
SelectionCANDIDATE
ReviewFINAL
Anchor typePATENT
Anchor date2034-01-13
Patent anchor2034-01-13
Exclusivity anchor2025-10-06
Protection date2034-01-13
First Final ANDA—
Status event—

BYFAVO 2034 CANDIDATE: US9827251 GNR DS-equivalent through 2034-01-13; no later patent tail. DPW 2027-07-10 is an earlier DP listing; user classified comparison as DRAW on 2026-10-23.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
104723652027-07-10U U-2968———
———
109612502027-07-10DP/U U-2968———
———
97770072027-07-10DP ————
———
99147382027-07-10DP ————
———
100523342031-11-07U U-2968———
———
101952102031-11-07U U-2968———
———
103428002031-11-07U U-2968———
———
107225222031-11-07U U-2968———
———
97375472031-11-07U U-2968———
———
95612362033-04-30U U-2968———
———
98272512034-01-13U U-2968NYDS_EQUIVALENT
| BYFAVO_DS_EQ_20261023: DS-equivalent GNR adjudication, not TRUE_DS; anchor 2034-01-13.
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
No generic approval facts are linked to this product.

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 0 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
No final-approval records are linked to this product.
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.